fda safety communication semaglutide vision loss naion 2025 The obesity drug (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added Semaglutide Once Again Linked to

Wegovy should be stopped at least two months before an IVF cycle begins

Before starting GLP-1 treatment , inform your GP about: Current or previous anxiety disorders , including generalised anxiety disorder, panic disorder, social anxiety, or health anxiety Other mental health conditions such as depression, eating disorders, or obsessive-compulsive disorder Current psychiatric medications , as weight loss may affect medication requirements though GLP-1 medications themselves have few direct drug interactions Previous experiences with weight loss or diabetes medications and any associated mood changes Your support network and coping strategies for managing stress and anxiety Your GP can help establish baseline mental health status and develop a monitoring plan

Ozempic is also approved to lower the risk of a major cardiovascular event (like a heart attack or stroke) in patients with type 2 diabetes, as well as to reduce the risk of worsening kidney disease and heart-related death in patients with type 2 diabetes (injection form)

Foundayo is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)